Coronary Vasomotion One Year after Drug-Eluting Stent Implantation: Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents

被引:10
|
作者
Hamilos, Michalis [1 ]
Ribichini, Flavio [2 ]
Ostojic, Miodrag C. [3 ]
Ferrero, Valeria [2 ]
Orlic, Dejan [3 ]
Vassanelli, Corrado [2 ]
Karanovic, Nevena [3 ]
Sarno, Giovanna [4 ]
Cuisset, Thomas [4 ]
Vardas, Panos E. [1 ]
Wijns, William [4 ]
机构
[1] Univ Hosp Heraklion, Dept Cardiol, Iraklion, Greece
[2] Univ Verona, Dept Biomed Sci & Surg, I-37100 Verona, Italy
[3] Clin Ctr Serbia, Dept Cardiol, Univ Inst Cardiovasc Dis, Belgrade, Serbia
[4] Onze Lieve Vrouw Hosp, Cardiovasc Ctr Aalst, B-9300 Aalst, Belgium
关键词
Drug-eluting stents; Coronary vasomotion; Endothelium; FOLLOW-UP; DYSFUNCTION; THROMBOSIS; SYSTEM;
D O I
10.1007/s12265-014-9568-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
First-generation drug-eluting stents (DES) have been associated with impaired localized coronary vasomotion and delayed endothelialization. We aimed to compare coronary vasomotion after implantation of a newer-generation everolimus-eluting stent (EES), with a first-generation paclitaxel-eluting stent (PES). Coronary vasomotion was studied in 19 patients with EES and 13 with PES. Vasomotor response was measured proximally and distally to the stent and in a remote vessel (reference segment). Quantitative coronary angiography was performed offline. Endothelium independent vasomotion did not differ significantly between the two groups. EES showed significant vasodilatation while PES showed vasoconstriction at both proximal (+4.5 +/- 3.6 vs -4.2 +/- 6.9, p < 0.001) and distal (+4.6 +/- 7.9 vs -4.8 +/- 9.3, p = 0.003) segments. The reference segment did not show any significant difference in vasodilatation between the two groups (+9.8 +/- 6.4 vs +7.2 +/- 5.2, p = 0.17). Endothelium-dependent vasomotion at adjacent stent segments is relatively preserved after EES implantation while vasoconstriction was observed after PES implantation.
引用
收藏
页码:406 / 412
页数:7
相关论文
共 50 条
  • [21] Three-year clinical outcomes after treatment of drug-eluting Stent restenosis with paclitaxel-eluting balloon vs. everolimus-eluting stent
    Almalla, M.
    Reith, S.
    Vogt, F.
    Marx, N.
    Schroeder, J.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1166 - 1166
  • [22] Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents
    Serruys, Patrick W.
    Silber, Sigmund
    Garg, Scot
    van Geuns, Robert Jan
    Richardt, Gert
    Buszman, Pawel E.
    Kelbaek, Henning
    van Boven, Adrianus Johannes
    Hofma, Sjoerd H.
    Linke, Axel
    Klauss, Volker
    Wijns, William
    Macaya, Carlos
    Garot, Philippe
    DiMario, Carlo
    Manoharan, Ganesh
    Kornowski, Ran
    Ischinger, Thomas
    Bartorelli, Antonio
    Ronden, Jacintha
    Bressers, Marco
    Gobbens, Pierre
    Negoita, Manuela
    van Leeuwen, Frank
    Windecker, Stephan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (02): : 136 - 146
  • [23] Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease
    Dangas, George D.
    Serruys, Patrick W.
    Kereiakes, Dean J.
    Hermiller, James
    Rizvi, Ali
    Newman, William
    Sudhir, Krishnankutty
    Smith, Robert S., Jr.
    Cao, Sherry
    Theodoropoulos, Kleanthis
    Cutlip, Donald E.
    Lansky, Alexandra J.
    Stone, Gregg W.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2013, 6 (09) : 914 - 922
  • [24] The Real World Experience of the Everolimus-Eluting Coronary Stent System: Audit of Everolimus-Eluting Coronary Stents
    Aldous, Sally
    Smyth, David
    Blake, James
    McClean, Dougal
    Elliott, John
    [J]. JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2011, 24 (03) : 241 - 246
  • [25] Coronary aneurysm after implantation of a paclitaxel-eluting stent
    Vik-Mo, H
    Wiseth, R
    Hegbom, K
    [J]. SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2004, 38 (06) : 349 - 352
  • [26] Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients With Acute and Stable Coronary Syndromes Pooled Results From the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials
    Planer, David
    Smits, Pieter C.
    Kereiakes, Dean J.
    Kedhi, Elvin
    Fahy, Martin
    Xu, Ke
    Serruys, Patrick W.
    Stone, Gregg W.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (10) : 1104 - 1115
  • [27] Everolimus-eluting coronary stents
    Saez, Alejandro
    Moreno, Raul
    [J]. MEDICAL DEVICES-EVIDENCE AND RESEARCH, 2010, 3 : 51 - 56
  • [28] Everolimus-eluting coronary stents
    Saez, Alejandro
    Moreno, Raul
    [J]. Medical Devices: Evidence and Research, 2010, 3 (01) : 51 - 56
  • [29] Everolimus-Eluting Versus Paclitaxel-Eluting Stents for Treatment of Bare Metal Stent Restenosis
    Almalla, Mohammad
    Schroeder, Joerg W.
    Pross, Verena
    Stegemann, Emilia
    Marx, Nikolaus
    Hoffmann, Rainer
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (04): : 518 - 522
  • [30] Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease
    Zhang, Feng
    Dong, Lili
    Qian, Juying
    Ge, Junbo
    [J]. ANNALS OF MEDICINE, 2011, 43 (01) : 75 - 79